<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609815</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-INTESTINE2015</org_study_id>
    <nct_id>NCT02609815</nct_id>
  </id_info>
  <brief_title>Initial Combination of Gemigliptin and Metformin on Microbiota Change</brief_title>
  <acronym>INTESTINE</acronym>
  <official_title>Effect of INitial Combination Therapy With GEmigliptin and Metformin on Microbiota Change and Glycemic Control in patientS With Type 2 DIabetes aNd ObEsity (INTESTINE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate gut microbiota change and glucose lowering effect
      of initial combination therapy of gemigliptin and metformin compared to glimepiride and
      metformin in obese patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese type 2 diabetes patients who were not treated with anti-diabetic medication within 6
      weeks, were randomly assigned to gemigliptin/metformin or sulphonylurea/metformin. After 24
      week treatment, gut microbiota composition change, glucose lowering effect, body weight, and
      gut hormones were compared between two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>gut microbiota composition change from baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>Analysis of gut microbiota composition at class, genus, and species levels before and after treatment. Inter-individual changes of gut microbiota changes were analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c change</measure>
    <time_frame>24 weeks</time_frame>
    <description>HbA1c change from baseline to 24 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Using bioimpedance analysis, muscle mass and total and visceral fat mass were analyzed after 24 week treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Beta-cell function</measure>
    <time_frame>24 weeks</time_frame>
    <description>HOMA-beta and insulinogenic index calculated before and after treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>GLP-1</measure>
    <time_frame>24 weeks</time_frame>
    <description>Plasma levels of GLP-1 during 75g OGTT.</description>
  </other_outcome>
  <other_outcome>
    <measure>GIP</measure>
    <time_frame>24 weeks</time_frame>
    <description>Plasma levels of GIP during 75g OGTT.</description>
  </other_outcome>
  <other_outcome>
    <measure>PYY</measure>
    <time_frame>24 weeks</time_frame>
    <description>Plasma levels of PYY during 75g OGTT.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>gemigliptin/metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>zemimet-SR 50/1000 mg x 1 tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glimepiride/metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amaryl-Mex 1/500 mg x 2 tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemigliptin/metformin</intervention_name>
    <description>zemimet-SR 50/1000 mg x 1 tablet</description>
    <arm_group_label>gemigliptin/metformin</arm_group_label>
    <other_name>Zemimet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride/metformin</intervention_name>
    <description>amaryl-Mex 1/500 mg x 2 tablets</description>
    <arm_group_label>glimepiride/metformin</arm_group_label>
    <other_name>Amarylmex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Drug naive (no anti-diabetic medication within 6 weeks)

          -  HbA1c &gt;= 7.5%

          -  BMI &gt;= 25.0 kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes

          -  DKA, HHS

          -  history of hypersensitivity to sulphonylurea, metformin or DPP-4 inhibitor

          -  Gestational diabetes mellitus

          -  Serum Cr &gt;1.5 mg/dL (male), &gt;1.4mg/dL (female)

          -  Abnormal liver function test

          -  Anti-obesity medication within 3 months

          -  Gastrointestinal motility drug, laxatives within 3 months

          -  History of major gastrointestinal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae Jung Oh</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae Jung Oh</last_name>
    <phone>82-31-787-7078</phone>
    <email>ohtjdm@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Lim, MD, PHD</last_name>
      <phone>82-31-787-7035</phone>
      <email>limsoo@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Tae Jung Oh, MD, PHD</last_name>
      <phone>82-31-787-7078</phone>
      <email>ohtjmd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Soo Lim, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Soo Lim</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

